/
HIND
$2.13-$0.03 (-1.39%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$15.2M
7M shares
52-week range
$1.75 – $16.00
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
14.81%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-11.87
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $606.7K | $15.1M | $11.3M | $13.6M | $11.2M | $8.7M | $8.0M | $319.7K |
| Cost of revenue | $164.3K | $5.8M | $5.0M | $5.3M | $4.4M | $3.1M | $2.9M | $112.9K |
| Gross profit | $442.4K | $9.3M | $6.3M | $8.3M | $6.8M | $5.5M | $5.1M | $206.8K |
| Gross margin | 72.9% | 61.7% | 55.4% | 61.4% | 60.5% | 63.9% | 63.2% | 64.7% |
| R&D | $5.7M | $3.1M | $3.5M | $2.4M | $2.5M | $2.3M | $1.8M | $588.3K |
| Operating income | −$38.5M | −$24.5M | −$12.5M | −$57.9M | −$27.1M | −$14.6M | −$7.7M | −$2.7M |
| EBITDA | −$37.0M | −$72.9M | −$18.1M | −$60.6M | −$44.3M | −$11.2M | −$6.6M | −$10.3M |
| Net income | −$81.2M | −$74.2M | −$21.6M | −$63.1M | −$46.2M | −$11.4M | −$7.1M | −$10.3M |
| Net margin | -13375.7% | -491.8% | -191.4% | -464.3% | -411.2% | -131.2% | -89.1% | -3209.7% |
| EPS (diluted) | -4270786.00 | -1094068.00 | -503023.26 | -419004.00 | -157897.00 | -2771.94 | -345.74 | -4.75 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $300000 | $-0.70 | $-0.70–$-0.70 | 1 |
| 2027 | $500000 | $-0.92 | $-0.92–$-0.92 | 1 |
| 2028 | $17M | $-0.85 | $-0.85–$-0.85 | 1 |
| 2029 | $26M | $0.39 | $0.39–$0.39 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.85
Price
$2.13
Implied downside
-13%
Peer comparison
Vyome Holdings, Inc. Common Stock
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
vyometx.com- Employees
- 18
- IPO / List date
- Aug 15, 2025
- HQ
- SAN CLEMENTE, CA
Held by traders on TradeandTell
No one on the platform currently holds HIND.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in HIND as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded HIND yet.
